Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
E: investor.relations@bms.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
32,500
Bristol-Myers Squibb Co News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.30 | 66.70 | 0.77% |
| CAC 40 | 7,869.43 | 125.51 | 1.62% |
| DAX 40 | 23,050.15 | 413.24 | 1.83% |
| Dow JONES (US) | 46,124.06 | 84.41 | -0.18% |
| FTSE 100 | 10,074.24 | 109.08 | 1.09% |
| HKSE | 25,335.95 | 272.24 | 1.09% |
| NASDAQ | 21,761.89 | 184.87 | -0.84% |
| Nikkei 225 | 53,749.62 | 1,497.34 | 2.87% |
| NZX 50 Index | 12,929.30 | 227.55 | 1.79% |
| S&P 500 | 6,556.37 | 24.63 | -0.37% |
| S&P/ASX 200 | 8,534.30 | 45.70 | 0.54% |
| SSE Composite Index | 3,931.84 | 50.56 | 1.30% |